Literature DB >> 27055398

Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.

Ruud C Wortel1, Luca Incrocci1, Floris J Pos2, Uulke A van der Heide2, Joos V Lebesque2, Shafak Aluwini1, Marnix G Witte2, Wilma D Heemsbergen3.   

Abstract

PURPOSE: Technical developments in the field of external beam radiation therapy (RT) enabled the clinical introduction of image guided intensity modulated radiation therapy (IG-IMRT), which improved target conformity and allowed reduction of safety margins. Whether this had an impact on late toxicity levels compared to previously applied three-dimensional conformal radiation therapy (3D-CRT) is currently unknown. We analyzed late side effects after treatment with IG-IMRT or 3D-CRT, evaluating 2 prospective cohorts of men treated for localized prostate cancer to investigate the hypothesized reductions in toxicity. METHODS AND MATERIALS: Patients treated with 3D-CRT (n=189) or IG-IMRT (n=242) to 78 Gy in 39 fractions were recruited from 2 Dutch randomized trials with identical toxicity scoring protocols. Late toxicity (>90 days after treatment) was derived from self-assessment questionnaires and case report forms, according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG-EORTC) scoring criteria. Grade ≥2 endpoints included gastrointestinal (GI) rectal bleeding, increased stool frequency, discomfort, rectal incontinence, proctitis, and genitourinary (GU) obstruction, increased urinary frequency, nocturia, urinary incontinence, and dysuria. The Cox proportional hazards regression model was used to compare grade ≥2 toxicities between both techniques, adjusting for other modifying factors.
RESULTS: The 5-year cumulative incidence of grade ≥2 GI toxicity was 24.9% for IG-IMRT and 37.6% following 3D-CRT (adjusted hazard ratio [HR]: 0.59, P=.005), with significant reductions in proctitis (HR: 0.37, P=.047) and increased stool frequency (HR: 0.23, P<.001). GU grade ≥2 toxicity levels at 5 years were comparable with 46.2% and 36.4% following IG-IMRT and 3D-CRT, respectively (adjusted HR: 1.19, P=.33). Other strong predictors (P<.01) of grade ≥2 late toxicity were baseline complaints, acute toxicity, and age.
CONCLUSIONS: Treatment with IG-IMRT reduced the risk of late grade ≥2 complications, whereas GU toxicities remained comparable. This clinically relevant observation demonstrates that IMRT and image-guidance should therefore be the preferred treatment option, provided that margin reduction is implemented with caution.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27055398     DOI: 10.1016/j.ijrobp.2016.01.031

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  The scope, presentation, and management of genitourinary complications in patients presenting with high-grade urethral complications after radiotherapy for prostate cancer.

Authors:  R Christopher Doiron; Jon Witten; Keith F Rourke
Journal:  Can Urol Assoc J       Date:  2021-01       Impact factor: 1.862

2.  Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.

Authors:  A Zapatero; M Roch; D Büchser; P Castro; L Fernández-Banda; G Pozo; O Liñán; C Martin de Vidales; A Cruz-Conde; F García-Vicente
Journal:  Clin Transl Oncol       Date:  2017-04-03       Impact factor: 3.405

3.  Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  B A Jereczek-Fossa; A Maucieri; G Marvaso; S Gandini; C Fodor; D Zerini; G Riva; O Alessandro; A Surgo; S Volpe; G Fanetti; S Arculeo; M A Zerella; S Parisi; P Maisonneuve; A Vavassori; F Cattani; R Cambria; C Garibaldi; A Starzyńska; G Musi; O De Cobelli; M Ferro; F Nolè; D Ciardo; R Orecchia
Journal:  Med Oncol       Date:  2018-11-27       Impact factor: 3.064

4.  Treatment of Localized and Locally Advanced, High-Risk Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries.

Authors:  Raja Khauli; Robson Ferrigno; Gustavo Guimarães; Muhammad Bulbulan; Pedro Luiz Serrano Uson Junior; Bernardo Salvajoli; Daniel Moore Freitas Palhares; Douglas Racy; Erlon Gil; Fernando Freire de Arruda; Gustavo Caserta Lemos; Gustavo Franco Carvalhal; Icaro Thiago de Carvalho; Igor Austin Fernandes Martins; Ivan Frederico Pinto Gimpel; João Victor Salvajoli; José Luis Chambo; José Pontes; Leopoldo Alves Ribeiro Filho; Lucas Nogueira; Marcelo Roberto Pereira Freitas; Marcelo Wroclawski; Marco Antonio Arap; Marcus Vinicius Sadi; Rafael Coelho; Rafael Gadia; Rodrigo Antonio Ledezma Roja; Rodrigo de Moraes Hanriot; Ronaldo Baroni; Stenio Zequi; William Carlos Nahas; Wladimir Alfer; Fernando Cotait Maluf
Journal:  JCO Glob Oncol       Date:  2021-04

5.  Volumetric-Modulated Arc Radiotherapy with Daily Image-Guidance Carries Better Toxicity Profile for Higher Risk Prostate Cancer.

Authors:  Ahmad I Ghanem; Amr A Elsaid; Mohamed A Elshaikh; Gehan A Khedr
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

Review 6.  A Ten-year-long Update on Radiation Proctitis Among Prostate Cancer Patients Treated With Curative External Beam Radiotherapy.

Authors:  Gianluca Ferini; Stefano Pergolizzi
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

Review 7.  Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers.

Authors:  Theresa A Lawrie; John T Green; Mark Beresford; Linda Wedlake; Sorrel Burden; Susan E Davidson; Simon Lal; Caroline C Henson; H Jervoise N Andreyev
Journal:  Cochrane Database Syst Rev       Date:  2018-01-23

8.  Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications.

Authors:  Calyn R Moulton; Michael J House; Victoria Lye; Colin I Tang; Michele Krawiec; David J Joseph; James W Denham; Martin A Ebert
Journal:  Radiat Oncol       Date:  2016-10-31       Impact factor: 3.481

9.  Manganese porphyrin, MnTE-2-PyP, treatment protects the prostate from radiation-induced fibrosis (RIF) by activating the NRF2 signaling pathway and enhancing SOD2 and sirtuin activity.

Authors:  Shashank Shrishrimal; Arpita Chatterjee; Elizabeth A Kosmacek; Paul J Davis; J Tyson McDonald; Rebecca E Oberley-Deegan
Journal:  Free Radic Biol Med       Date:  2020-03-25       Impact factor: 7.376

10.  Associations between clinical characteristics and tumor response to neoadjuvant chemoradiotherapy in rectal cancer.

Authors:  Xiaolin Pang; Yuanhong Gao; Hanchen Yi; Hailing Liu; Shuai Liu; Jian Zheng
Journal:  Cancer Med       Date:  2021-06-15       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.